Christian Medical College

Ludhiāna, India

Christian Medical College

Ludhiāna, India
SEARCH FILTERS
Time filter
Source Type

News Article | April 26, 2017
Site: www.eurekalert.org

AUGUSTA, Ga. (April 26, 2017) - Dr. Kapil Sethi, a neurologist and former director of the Movement Disorders Program at the Medical College of Georgia at Augusta University, is the 2017 recipient of the Association of Indian Neurologists in America's Lifetime Achievement Award. The award recognizes a leader in neurology based on his dedication to advancing the training of North American neurologists of Indian origin and promoting innovation and research in the field of neurology. Sethi received the award at the group's annual meeting this week in Boston. Sethi was appointed director of the Movement Disorders Program in 1985 and served in that capacity until last year. He also was Director of the National Parkinson's Foundation Center of Excellence at AU Health from 2000-09. An internationally known expert in movement disorders, Sethi is currently a principal investigator on a study to determine whether a constant subcutaneous infusion of apomorphine over 18 hours daily can help "rescue" Parkinson's patients from bouts of immobility and smooth out their movements. The MCG and AU Movement Disorders Program is among 20 sites across the nation enrolling up to 60 patients in the study. He is project director for the Parkinson Research Alliance of India, an alliance working to bring more clinical trials for Parkinson's disease to India. He is a fellow of the American Academy of Neurology and the Royal College of Physicians and is a member of the American Neurological Association, the Movement Disorder Society and the American Association of Physicians from India. Sethi is former treasurer for the American Academy of Neurology Foundation and a former member of the Board of Directors of the American Academy of Neurology. He has served on the Fundraising and Program committees for the World Parkinson Congress and on the World Health Organization's Advisory Board for Revision of ICD-10 Diseases of the Nervous System. In 2009, he served on the Clinical Intervention Awards Program Review Committee for the Michael J. Fox Foundation for Parkinson's disease. He is former president of the Association of Indian Neurologists in America. He is a former editorial reviewer for high-end scientific journals like The New England Journal of Medicine, Brain, Journal of Neurology, Neurosurgery & Psychiatry, PD and Related Disorders and Movement Disorders. He was listed among America's Top Doctors for 16 consecutive years, from 2001-17, by Castle Connolly. Sethi was born in Sultanpur, India, graduated from Christian Medical College in Ludhiana, and completed much of his postgraduate training, including fellowship training in neurology, in India. He was a research fellow at Charing Cross Group of Hospitals and Medical School in London and completed additional neurology training at the Sub-Regional Unit of Neurology for Welsh National School of Medicine and Morriston Hospital in the United Kingdom before coming to MCG for his final two years of residency.


News Article | April 17, 2017
Site: www.prweb.com

Dr. Jai Joshi is an experienced, board certified medical oncologist. Dr. Joshi received his medical degree and completed his internal medicine residence at the Christian Medical College in Ludhiana, India. He has trained at some of the best institutions in the United States: fellowship in hematology/oncology at the National Cancer Institute (NIH) and the University of Colorado Medical Center, then assistant professor of medicine and oncology at the Johns Hopkins School of Medicine and at MD Anderson Cancer Center. Dr. Joshi was awarded the prestigious RO1 Grant Award from the NCI, NIH to study infections in patients with acute leukemia. He has authored book chapters and Editorials and published extensively in peer-reviewed journals making an impact in the field of cancer. He has awarded Excellence in Teaching Awards with Hopkins, including one from the Department of Medicine, the Johns Hopkins University/Sinai Hospital of Baltimore for enthusiastic support and dedication to resident education including the compilation of the “Joshi Handbooks in Medicine”. He is the subject of biographical record in Who’s Who in Frontier Science and Technology, International Who’s Who of Contemporary Achievement and in Men of Achievement. His accomplishments appear in the International Biographical Center Register of Profiles of Personalities of America. Since then, Dr. Joshi has helped initiate new cancer programs and academic oncology practices in various small towns and hospitals (Jasper, IN, Laredo and Eagle Pass, TX), with citywide hospital-based tumor boards and actively engaged in community seminars, and radio and television talk shows. Dr. Joshi's patient philosophy is that interactions between a good doctor and his patients will always bring forth the physician's humanity in amazing light.


Anand R.,Christian Medical College | Gill K.D.,Jawaharlal Institute of Postgraduate Medical Education & Research | Mahdi A.A.,University of Lucknow
Neuropharmacology | Year: 2014

Alzheimer's disease (AD) is the most common cause of dementia worldwide. The etiology is multifactorial, and pathophysiology of the disease is complex. Data indicate an exponential rise in the number of cases of AD, emphasizing the need for developing an effective treatment. AD also imposes tremendous emotional and financial burden to the patient's family and community. The disease has been studied over a century, but acetylcholinesterase inhibitors and memantine are the only drugs currently approved for its management. These drugs provide symptomatic improvement alone but do less to modify the disease process. The extensive insight into the molecular and cellular pathomechanism in AD over the past few decades has provided us significant progress in the understanding of the disease. A number of novel strategies that seek to modify the disease process have been developed. The major developments in this direction are the amyloid and tau based therapeutics, which could hold the key to treatment of AD in the near future. Several putative drugs have been thoroughly investigated in preclinical studies, but many of them have failed to produce results in the clinical scenario; therefore it is only prudent that lessons be learnt from the past mistakes. The current rationales and targets evaluated for therapeutic benefit in AD are reviewed in this article. This article is part of the Special Issue entitled 'The Synaptic Basis of Neurodegenerative Disorders'. © 2013 Elsevier Ltd. All rights reserved.


Srivastava A.,Christian Medical College
Haemophilia | Year: 2014

Care for people with haemophilia (PWH) has improved much over the last two decades leading to near normal lives for those receiving early regular prophylaxis with clotting factor concentrates (CFC). Yet, there are significant limitations of those practices. In the absence of a well-defined optimal prophylaxis protocol, there are wide variations in practices with a two to threefold difference in doses. In those parts of the world where there are constraints on the availability of CFC, episodic replacement remains the norm for most patients even though it is evident that this does not change the natural history of the disease over a wide range of doses. Suitable prophylactic protocols therefore need to be developed wherever possible at these doses. Finally, there are only limited data on long-term outcomes in haemophilia from anywhere in the world. The practice of documenting specific outcomes as part of the regular evaluation of PWH needs to be established and the appropriate instruments used to assess them. Definitions of clinical events and endpoints of interventions in clinical studies are being developed to help such data collection. The correlations between different replacement therapy protocols and specific outcomes will help define what is best at different dose levels. Such data will allow better health planning and treatment choices throughout the world. © 2014 John Wiley & Sons Ltd.


Peedicayil J.,Christian Medical College
Current Pharmaceutical Design | Year: 2014

Cognitive disorders are an important group of disorders affecting the brain for which currently used drugs are often of low efficacy and mainly of symptomatic value. There is increasing evidence suggesting that epigenetic changes in gene expression underlie cognitive disorders. Advances in epigenetics have given rise to a new class of drugs, epigenetic drugs, that reverse epigenetic changes in gene expression. At present most work on epigenetic drugs focuses on two types of drugs: histone deacetylase (HDAC) inhibitors, and drugs targeting DNA methylation. This article describes the role of epigenetic drugs in treating cognitive disorders, focusing on Alzheimer's disease, Huntington's disease, and Parkinson's disease. Epigenetic drugs may improve the clinical management of patients with cognitive disorders. © 2014 Bentham Science Publishers.


Simha A.,Christian Medical College
The Cochrane database of systematic reviews | Year: 2013

Neovascular glaucoma (NVG) is a potentially blinding secondary glaucoma. It is caused by the formation of abnormal new blood vessels which prevent normal drainage of aqueous from the anterior segment of the eye. Anti-vascular endothelial growth factor (anti-VEGF) agents are specific inhibitors of the primary mediators of neovascularization. Studies have reported the effectiveness of anti-VEGFs for the control of intraocular pressure (IOP) in NVG. To compare the IOP lowering effects of intraocular anti-VEGF agents to no anti-VEGF treatment, as an adjunct to existing modalities for the treatment of NVG. We searched CENTRAL (which contains the Cochrane Eyes and Vision Group Trials Register) (The Cochrane Library 2012, Issue 12), Ovid MEDLINE, Ovid MEDLINE In-Process and Other Non-Indexed Citations, Ovid MEDLINE Daily, Ovid OLDMEDLINE, (January 1950 to January 2013), EMBASE (January 1980 to January 2013), Latin American and Caribbean Literature on Health Sciences (LILACS) (January 1982 to January 2013), the metaRegister of Controlled Trials (mRCT) (www.controlled-trials.com), ClinicalTrials.gov (www.clinicaltrials.gov/) and the WHO International Clinical Trials Registry Platform (ICTRP) (www.who.int/ictrp/search/en). We did not use any date or language restrictions in the electronic searches for trials. We last searched the electronic databases on 11 January 2013. We included randomized controlled trials (RCTs) and quasi-RCTs of people treated with anti-VEGF agents for NVG. Two authors independently assessed the search results for trials to be included in the review. Discrepancies were resolved by discussion with a third author. Since no trial met our inclusion criteria, no assessment of risk of bias or meta-analysis was undertaken. No RCTs were found that met the inclusion criteria for this review. Two RCTs of anti-VEGF agents for treating NVG were not included in the review due to the heterogeneity and uncontrolled assignment of adjunct treatments received by the study participants. Currently available evidence is insufficient to evaluate the effectiveness of anti-VEGF treatments, such as intravitreal ranibizumab or bevacizumab, as an adjunct to conventional treatment in lowering IOP in NVG. Well designed RCTs are needed to address this issue, particularly trials that evaluate long-term (at least six months) benefits and risks since the effects of anti-VEGF agents may be short-term only. An RCT comparing anti-VEGF agents with no anti-VEGF agents taking into account the need for co-interventions, such as panretinal photocoagulation (PRP), glaucoma shunt procedures, cyclodestructive procedures, cataract surgery, and deep vitrectomy, could be of use to investigate the additional beneficial effect of anti-VEGF agents in treating NVG. Since decisions for when and which co-interventions should be used are based on clinical criteria, they would not be appropriate for randomization. However, the design of a study on this topic should aim to balance groups by stratification of co-intervention at time of randomization or by enrolling a sufficient number of participants to conduct subgroup analysis by co-interventions (ideally 15 participants per treatment group for each subgroup). Alternatively, the inclusion criteria for a trial could limit participants to those who receive the same co-intervention.


Chaturvedi S.,Christian Medical College
The Cochrane database of systematic reviews | Year: 2014

Hypertension is a major risk factor for stroke, coronary artery disease and kidney damage in adults. There is a paucity of data on the long-term sequelae of persistent hypertension in children, but it is known that felodipine,one trial, n = 133) was not effective in reducing systolic blood pressure (-0.62 mmHg, 95% CI -2.97 to 1.73) or diastolic blood pressure (-1.86 mmHg, 95% CI -5.23 to 1.51) when compared with placebo. Further, there was no consistent dose response observed among any of the drug classes. The adverse events associated with the antihypertensive agents were mostly minor and included headaches, dizziness and upper respiratory infections. Overall, there are sparse data informing the use of antihypertensive agents in children, with outcomes reported limited to blood pressure and not end organ damage. The most data are available for candesartan, for which there is low-quality evidence of a modest lowering effect on blood pressure. We did not find evidence of a consistent dose response relationship for escalating doses of angiotensin receptor blockers, calcium channel blockers or angiotensin-converting enzyme inhibitors. All agents appear safe, at least in the short term.


Patent
Center For Bioseparation Technology Vit and Christian Medical College | Date: 2013-09-11

A process of producing heavy chain peptide and/or light chain peptide of recombinant Factor VIII protein includes using the Pichia pastoris expression system. A process of producing a functional recombinant Factor VIII protein by reconstituting the Heavy chain and Light chain produced using said Pichia pastoris expression system. The said functional recombinant Factor VIII protein shows improved activity and therefore is used in the management of haemophilia.


Patent
Christian Medical College | Date: 2013-11-06

The present disclosure relates to recombinant adeno-associated virus (AAV) vector serotype, wherein the capsid protein of AAV serotypes is mutated at single or multiple sites. The disclosure further relates to an improved transduction efficiency of these mutant AAV serotypes. The AAV serotypes disclosed are AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10. The instant disclosure relates to nucleotide sequences, recombinant vector, methods and kit thereof.


Patent
Center For Bioseparation Technology Vit and Christian Medical College | Date: 2013-09-12

A double mutant B-domain deleted Factor VIII gene having mutations at Phe309Ser and Asp519Val, respectively, is disclosed for use in the field of haemophilia therapeutics. The disclosure a double mutant B-domain deleted Factor VIII protein having mutations at Phe309Ser and Asp519Val respectively, is also disclosed, as well as methods of producing the same. The B-domain deleted Factor VIII protein having mutations at Phe309Ser and Asp519Val shows enhanced activity and stability and therefore is used in the management of haemophilia.

Loading Christian Medical College collaborators
Loading Christian Medical College collaborators